TITLE

Pharmacodynamics, Pharmacokinetics, and Tolerability of Intravenous or Subcutaneous GC1113, a Novel Erythropoiesis-Stimulating Agent

AUTHOR(S)
Han, HyeKyung; Lee, Jongtae; Shin, Donghoon; Shin, Kwang-Hee; Jeon, Hyewon; Lim, Kyoung; Yoon, Seo; Shin, Sang-Goo; Jang, In-Jin; Cho, Joo-Youn; Yu, Kyung-Sang
PUB. DATE
June 2014
SOURCE
Clinical Drug Investigation;Jun2014, Vol. 34 Issue 6, p373
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and Objectives: GC1113, a hybrid Fc-fused erythropoietin, is a novel erythropoiesis-stimulating agent that is expected to have an extended duration of action. The preclinical data showed that the hemoglobin increase lasted longer following GC1113 administration than it did following the administration of darbepoetin alfa (NESP). This study aimed to investigate the pharmacodynamic and pharmacokinetic characteristics and tolerability profiles of GC1113 in humans after single intravenous or subcutaneous administration and to compare the results with those for darbepoetin alfa. Methods: A dose-block randomized, placebo- and active-controlled, dose-escalation phase I clinical trial was conducted in 96 healthy volunteers. Blood samples were collected before and up to 672 h after drug administration and the serum erythropoietin concentration following the GC1113 or darbepoetin alfa administration was measured by an ELISA. The reticulocyte counts were measured for pharmacodynamic assessments. Pharmacokinetic and pharmacodynamic parameters were determined using non-compartmental methods. Results: The reticulocyte count-time profiles in the intravenous GC1113 3-5 μg/kg groups were comparable with those of the darbepoetin alfa 30 μg group. After subcutaneous administration of GC1113, reticulocyte count peaked later and decreased more slowly than it did following darbepoetin alfa administration. GC1113 (0.3-5 μg/kg intravenous, 1-8 μg/kg subcutaneous) was well-tolerated in the volunteers, and no immunogenicity was observed. Conclusion: GC1113 was tolerated and effective in the studied dose range; these findings could be applied to further clinical studies with patients.
ACCESSION #
96086414

 

Related Articles

  • Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial. Forni, Valentina; Bianchi, Giorgia; Ogna, Adam; Salvadé, Igor; Vuistiner, Philippe; Burnier, Michel; Gabutti, Luca // BMC Nephrology;2013, Vol. 14 Issue 1, p1 

    Background: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however...

  • Erythropoiesis stimulating agents: approaches to modulate activity. Sinclair, Angus M. // Biologics: Targets & Therapy;2013, Vol. 7, p161 

    Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may...

  • Foreword. Carrera, Fernando // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_4, piv1 

    An introduction to the journal is presented in which the editor discusses an article on haemoglobin (Hb) level stability because of erythropoiesis-stimulating agents (ESA), half-life of darbepoetin, and extended dosage of ESAs.

  • Erythropoietin use and abuse. John, M. Joseph; Jaison, Vineeth; Jain, Kunal; Kakkar, Naveen; Jacob, Jubbin J. // Indian Journal of Endocrinology & Metabolism;Mar2012, Vol. 16 Issue 2, p220 

    Recombinant human erythropoietin (rhEPO) is arguably the most successful therapeutic application of recombinant DNA technology till date. It was isolated in 1977 and the gene decoded in 1985. Since then, it has found varied applications, especially in stimulating erythropoiesis in anemia due to...

  • Identification of the long-acting erythropoiesis-stimulating agent darbepoetin alfa in human urine by liquid chromatography-tandem mass spectrometry. Okano, Masato; Sato, Mitsuhiko; Kageyama, Shinji // Analytical & Bioanalytical Chemistry;Feb2014, Vol. 406 Issue 5, p1317 

    The misuse of recombinant human erythropoietin (rhEPO) increases the proliferation/production of erythrocytes, which enhance oxygen transport capacities, and has grave consequences with respect to human health and fairness in sports. For sports drug testing, the current analytical methods for...

  • DIALYSIS ANAEMIA.  // Nephrology Dialysis Transplantation;May2014, Vol. 29 Issue suppl_3, piii491 

    No abstract available.

  • Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. Uemura, Osamu; Hattori, Motoshi; Hataya, Hiroshi; Ito, Shuichi; Ito, Naoko; Akizawa, Tadao // Clinical & Experimental Nephrology;Dec2014, Vol. 18 Issue 6, p932 

    Background: Darbepoetin alfa (DA) is beneficial for pediatric patients for its less injection frequency and greater maximum dose compared to recombinant human erythropoietin. Here, we evaluated pharmacokinetics of DA in Japanese pediatric patients with chronic kidney disease (CKD). Methods: CKD...

  • Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Carrera, Fernando; Disney, Alex; Molina, Manuel // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_4, piv19 

    The recombinant human erythropoietins epoetins alfa and beta have relatively short half-lives (∼24 h by subcutaneous route) and have traditionally been administered 2 or 3 times a week for the treatment of anaemia in patients with chronic kidney disease. However, multiple weekly injections...

  • A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. Schirm, Sibylle; Engel, Christoph; Loeffler, Markus; Scholz, Markus Scholz // Theoretical Biology & Medical Modelling;2014, Vol. 11 Issue 1, p2 

    Background Haematotoxicity of conventional chemotherapies often results in delays of treatment or reduction of chemotherapy dose. To ameliorate these side-effects, patients are routinely treated with blood transfusions or haematopoietic growth factors such as erythropoietin (EPO) or granulocyte...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics